Polymerase chain reaction adjustment in antimalarial trials: Molecular malarkey?

Journal of Infectious Diseases

Volumn 200, Issue 1, 2009, Pages 5-7

  Juliano, Jonathan J ^a   Taylor, Steve M ^b,c   Meshnick, Steven R ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; FANSIDAR;

AMPLICON; ANTIMALARIAL DRUG RESISTANCE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SCREENING; DRUG TREATMENT FAILURE; HUMAN; MALARIA; MALARIA FALCIPARUM; NOTE; PARASITEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT INFECTION; REINFECTION;

ANTIMALARIALS; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; POLYMERASE CHAIN REACTION; PYRIMETHAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFADOXINE;

EID: 67650652251     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/599379     Document Type: Note

References (12)

1. Faucher JF, Aubouy A, Adeothy A, et al. Corn parison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J Infect Dis 2009;200:57-65 (in this issue).
2. Stepniewska K, Taylor WR, Mayxay M, et al. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 2004; 48:4271-80.
3. Snounou G, Beck HP. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 1998; 14:462-7.
4. Collins WJ, Greenhouse B, Rosenthal PJ, Dorsey G. The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005. Malar J 2006; 5:122.
5. World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization, 2007.
6. Juliano JJ, Kwiek JJ, Cappell K, Mwapasa V, Meshnick SR. Minority-variant pfcrt K76T mutations and chloroquine resistance, Malawi. Emerg Infect Dis 2007; 13:872-7.
7. Liu S, Mu J, Jiang H, Su XZ. Effects of Plasmodium falciparum mixed infections on in vitro antimalarial drug tests and genotyping. Am J Trop Med Hyg 2008;79:178-84.
8. Greenhouse B, Dokomajilar C, Hubbard A, Rosenthal PJ, Dorsey G. Impact of transmis-sion intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob Agents Chemother 2007;51:3096-103.
9. Kwiek JJ, Alker AP, Wenink EC, Chaponda M, Kalilani LV, Meshnick SR. Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections. Antimicrob Agents Chemother 2007;51:521-7.
10. Gatton ML, Cheng Q. Can estimates of antimalarial efficacy from field studies be improved? Trends Parasitol 2008;24:68-73.
11. Bushman FD, Hoffmann C, Ronen K, et al. Massively parallel pyrosequencing in HIV research. AIDS 2008;22:1411-5.
12. Ngrenngarmlert W, Kwiek JJ, Kamwendo DD, et al. Measuring allelic heterogeneity in Plasmodium falciparum by a heteroduplex tracking assay. Am J Trop Med Hyg 2005;72:694-701.